Bicara Therapeutics Inc. BCAX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 63.22% | 56.43% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.84% | 59.98% | -- | -- | -- |
| Operating Income | -66.84% | -59.98% | -- | -- | -- |
| Income Before Tax | -80.88% | -70.64% | -- | -- | -- |
| Income Tax Expenses | -33.55% | -23.64% | -- | -- | -- |
| Earnings from Continuing Operations | -80.54% | -70.38% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.54% | -70.38% | -- | -- | -- |
| EBIT | -66.84% | -59.98% | -- | -- | -- |
| EBITDA | -66.80% | -59.95% | -- | -- | -- |
| EPS Basic | 2.58% | 87.21% | -- | -- | -- |
| Normalized Basic EPS | 2.52% | 87.23% | -- | -- | -- |
| EPS Diluted | 2.58% | 87.21% | -- | -- | -- |
| Normalized Diluted EPS | 2.52% | 87.23% | -- | -- | -- |
| Average Basic Shares Outstanding | 36.73% | 86.41% | -- | -- | -- |
| Average Diluted Shares Outstanding | 36.73% | 86.41% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |